Xeris Biopharma Holdings, Inc.
XERS
Positions held
Your positionsXERS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Xeris Biopharma is positioned in a growing sector with a focus on innovative drug delivery solutions, which can enhance patient compliance and improve therapeutic outcomes.
- Revenue increased by 11% compared to the prior quarter, reaching $92 million.
- The company has a strong gross margin of 86.4%, indicating effective cost management and pricing power.
- Despite the revenue growth, Xeris reported a net income loss of $31.1 million in the latest quarter, highlighting ongoing financial challenges.
- The operating margin has compressed to 5.6%, down from 9.5% in the previous quarter, indicating potential operational inefficiencies.
- The forward P/E ratio stands at 27.22, suggesting that the stock may be overvalued relative to its earnings potential.
Fundamentals
| Market cap | $1.86B | Enterprise value | $2.03B | Trailing P/E | — | Forward P/E | 27.54 |
| PEG | — | Price / book | -181.96 | Beta | 0.84 | Dividend yield | 0.00% |
| Revenue growth | 28.7% | Earnings growth | — | Gross margin | 86.6% | Operating margin | 5.6% |
| Profit margin | -5.1% | ROE | — | ROA | 6.1% | Debt / equity | — |
| Current ratio | 1.45 | Free cash flow | $52.45M | Analyst recommendation | strong_buy | Mean target | $12.86 |
| 52w high | $11.33 | 52w low | $5.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $92.1M | $83.1M | $85.8M | $74.4M | $71.5M | — |
| Op margin | 5.6% | 9.5% | 19.5% | 9.0% | 6.3% | — |
| Net income | -$31.1M | $2.2M | $11.1M | $0.6M | -$1.9M | — |
| Gross margin | 86.4% | 87.3% | 87.2% | 85.2% | 83.4% | — |
| Gross profit | $79.6M | $72.6M | $74.9M | $63.4M | $59.6M | — |
| Operating income | $5.2M | $7.9M | $16.8M | $6.7M | $4.5M | — |
- Revenue +11% vs prior quarter ($92M vs $83M).
- Gross margin 86.4% (was 87.3% prior quarter).
- Operating margin compressed to 5.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $292M | $203M | $164M | $110M | — |
| Op margin | 8.5% | -16.6% | -26.8% | -74.3% | — |
| Net income | $0.6M | -$54.8M | -$62.3M | -$94.7M | — |
| Gross margin | 85.4% | 81.9% | 82.5% | 79.5% | — |
| Gross profit | $249M | $166M | $135M | $87.6M | — |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | — |
Headlines — positive tone
• [OK · fundamentals] Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
News
2026-10-08 · Why Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring Debt
2026-10-02 · Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-09-30 · Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
2026-09-29 · Xeris Biopharma Holdings Insider Sold Shares Worth $250,000, According to a Recent SEC Filing
2026-09-29 · Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports
2026-09-29 · Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
2026-09-29 · Sector Update: Healthcare Stocks Decline Tuesday Afternoon
2026-09-29 · Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
2026-08-26 · Xeris Announces Details for XP-8121 Program Overview Webinar
2026-08-15 · Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121
2026-08-14 · Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain?
Price (daily)
Full chart · RSI · MACD · patterns